Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: A systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Erythropoietin as possible treatment of brain diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Cognitive impairments are a core feature of several neuropsychiatric disorders. A common biomarker for pro-cognitive effects may provide a much-needed tool to select amongst candidate treatments targeting cognition. The hippocampus is a promising biomarker for target-engagement due to the illness-associated morphological hippocampal changes across unipolar disorder (UD), bipolar disorder (BD) and schizophrenia (SCZ). Following the PRISMA guidelines, we searched PubMed and Embase, for clinical trials targeting cognition across neuropsychiatric disorders, with longitudinal structural magnetic resonance imaging (MRI) measures of the hippocampus. Five randomized and three open-label trials were included. Hippocampal volume increases were associated with treatment-related cognitive improvement following treatment with erythropoietin across UD, BD and SCZ, lithium treatment in BD and aerobic exercise in SCZ. Conversely, an exercise intervention in UD showed no effect on hippocampal volume or cognition. Together, these observations point to hippocampal volume change as a putative biomarker-model for cognitive improvement. Future cognition trials are encouraged to include MRI assessments pre- and post-treatment to assess the validity of hippocampal changes as a biomarker for pro-cognitive effects.

TidsskriftEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Udgave nummer3
Sider (fra-til)319-329
Antal sider11
StatusUdgivet - mar. 2019

Bibliografisk note

Copyright © 2019 Elsevier B.V. and ECNP. All rights reserved.

ID: 58079738